Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using the patient's own T-cells to target tumors.

Rakuten Medical has added to its tally of mega-rounds, pocketing another $100 million to push its lead light-based cancer ...

Amgen is getting down with Disco Pharmaceuticals, commissioning the German biotech to work on cancer therapies focused on a ...

CEO of two NASDAQ-listed companies and securing over $500 million in funding- Expertise in advanced therapeutics development ...

Proteins that are no longer needed, defective, or potentially harmful are labeled with a molecular "tag" and dismantled in ...

Collaboration with Amgen to advance a cancer target discovered using DISCO’s proprietary surfaceome mapping technology Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today ...

Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...

Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most ...

New findings reveal promising advancements in treating relapsed mantle cell lymphoma with BCL-2 inhibitors and novel agents, ...

Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...

Researchers at The University of Texas MD Anderson Cancer Center have discovered that targeting a specific immune process could help improve recovery ...